RxDoctor Payments Data

Anthony Osterman Pla, MD

Cardiovascular Disease · Springfield, MANPI 1851687388

Payments from drug & device makers

$3,572in general payments, 2019–2025

Across 177 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$895
  • Pfizer$711
  • E.r. Squibb & Sons, L.L.C.$372
  • Johnson & Johnson$278
  • Boehringer Ingelheim$209
  • Amgen$193
  • plus $914 from 14 others

What the payments were for

  • Food & beverage$3,47297%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,572 in reported general payments places this provider in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$215,531
Medicare patients
1,369
Services billed
3,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban403$496,470
EntrestoSacubitril/Valsartan216$282,382
FarxigaDapagliflozin Propanediol157$176,690
XareltoRivaroxaban40$45,246
Praluent PenAlirocumab45$39,027
Repatha SureclickEvolocumab28$36,698
Repatha SyringeEvolocumab28$27,538
DapagliflozinDapagliflozin Propanediol14$13,768
Metoprolol Succinate657$11,279
Ezetimibe244$11,211
Rosuvastatin Calcium405$10,038
Isosorbide Mononitrate ErIsosorbide Mononitrate349$6,857
Atorvastatin Calcium296$6,035
Enoxaparin Sodium21$3,399
Valsartan43$2,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$711$496,470403 claims
NovartisEntresto$895$282,382216 claims
AstraZenecaFarxiga$111$176,690157 claims
Johnson & JohnsonXarelto$278$45,24640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →